Quigley Co.: Asbestos Refractory Products & the Pfizer Connection

Quigley Co. History: Refractory Products and the Insulag Brand

Quigley Co. was founded in the early twentieth century as a specialty manufacturer of refractory materials—products designed to withstand extreme heat in industrial furnaces, kilns, ladles, and ovens. These materials are indispensable to industries such as steel production, iron casting, glass manufacturing, and cement production, where temperatures can exceed 2,000 degrees Fahrenheit and ordinary construction materials would fail almost instantly.

The company’s flagship product was Insulag, a refractory cement compound that used chrysotile asbestos as a key binding and insulating ingredient. Insulag was marketed as an all-purpose furnace lining cement and was available in multiple formulations suited to different temperature ranges and industrial applications. When workers applied, mixed, or disturbed Insulag, fine asbestos fibers were released into the air. Inhalation of these fibers—invisible to the naked eye and light enough to remain airborne for hours—is the primary mechanism by which asbestos causes mesothelioma, asbestos lung cancer, and asbestosis.

Beyond Insulag, Quigley also produced a range of other refractory cements, mortars, and coatings. Some products were sold under the Quigley name directly; others were distributed through industrial supply chains under private labels or as components in larger refractory systems. The breadth of Quigley’s product line meant that workers in virtually every major heavy industry in the United States had some chance of encountering Quigley asbestos materials on the job.

Refractory products require periodic maintenance, relining, and replacement. This meant that exposure was not a one-time event for many workers. Steel furnace liners, for example, might be torn out and replaced with new refractory material several times a year. Workers involved in this “tear-out” work—removing old, brittle refractory material—faced some of the heaviest asbestos fiber exposures of any industrial occupation. Insulag that had been heated and re-heated in service became highly friable, crumbling to dust at the slightest disturbance and releasing enormous quantities of asbestos fibers.

Quigley operated multiple manufacturing facilities across the eastern United States. The company supplied not only directly to industrial end-users but also to refractory contractors and distributors who resold and installed the products at client facilities. This layered distribution chain means that many affected workers never knew they were using a Quigley product specifically—they simply knew they were working with refractory cement, and the brand name, if visible at all, was on a bag that had already been emptied and discarded.

Pfizer’s Ownership and the Corporate Liability Controversy

In 1968, pharmaceutical and consumer products conglomerate Pfizer Inc. acquired Quigley Co. as part of a broader strategy to diversify its industrial chemical portfolio. At the time, Pfizer was not primarily known as a pharmaceutical company in the way it is today; the company had significant interests in specialty chemicals, minerals, and industrial products. Quigley fit neatly into this portfolio as a leading manufacturer in its niche.

The acquisition of Quigley was not, on its face, an asbestos transaction. Pfizer acquired a going business with valuable intellectual property, customer relationships, and manufacturing capabilities. The fact that Quigley’s products contained asbestos was industry-standard practice in 1968; asbestos had been used in refractory products for generations and was not yet subject to the regulatory restrictions that would come in the 1970s and beyond.

As asbestos litigation grew through the 1980s and into the 1990s, the accumulation of liability at Quigley became unmistakable. Tens of thousands of workers who had used Insulag and other Quigley products began filing lawsuits, claiming that the company had known about asbestos hazards for decades and had failed to warn workers or provide protective equipment. Internal documents produced in discovery in various cases revealed that asbestos industry knowledge of fiber health risks dated to at least the 1930s—knowledge that manufacturers like Quigley could not plausibly claim to have been unaware of.

For Pfizer, the situation created a controversial legal and ethical question: should a wealthy parent company be liable for the debts of a subsidiary it had acquired? Plaintiffs’ lawyers argued that Pfizer had both the resources to compensate victims and the corporate responsibility as the ultimate owner of Quigley. Pfizer resisted direct liability but ultimately agreed to contribute substantial funds to support the Quigley bankruptcy reorganization and trust, partly to protect itself from successor-liability and alter-ego claims that might otherwise have exposed Pfizer’s own assets directly.

The legal battles surrounding Quigley’s bankruptcy lasted for years and became a significant case study in how large corporations use Chapter 11 bankruptcy to manage mass tort asbestos liability. The court proceedings were watched closely by the asbestos litigation bar and corporate defense lawyers alike, as the outcome had broad implications for how parent-company liability would be treated in future asbestos bankruptcies.

Worker Exposure: Steelworkers, Foundry Workers, and Kiln Operators

The workers most affected by Quigley asbestos products were those employed in the heart of American heavy industry from the 1940s through the 1980s. Mesothelioma’s long latency period—typically 20 to 50 years between first exposure and diagnosis—means that workers exposed to Insulag in the 1960s or 1970s may only now be developing symptoms and receiving diagnoses.

Steel and iron foundry workers were among the most heavily exposed. Steelmaking furnaces required regular rebricking and relining with refractory materials, including Quigley’s products. Workers called “bricklayers” or “furnace liners” who mixed and applied refractory cement as part of their routine duties inhaled asbestos fibers on virtually every working day. Those assigned to tear-out work—demolishing spent furnace linings to prepare for fresh material—faced even higher exposure as crumbled, friable refractory material generated dense clouds of dust.

Kiln workers in cement, lime, and ceramics plants faced similar conditions. Rotary kilns used in cement production are massive structures that require periodic refractory maintenance. Workers who entered kilns for inspection or relining work, even briefly, could experience intense asbestos fiber exposure in confined spaces with limited ventilation.

Boilermakers and boiler room workers at power plants, chemical plants, and shipyards frequently encountered Quigley products used in conjunction with boiler insulation systems. Insulag was used not only as a furnace cement but also as a patching and repair compound in boiler applications, meaning boilermakers often applied it alongside pipe insulators and other tradespeople who were themselves applying other asbestos-containing materials.

Maintenance and construction workers at industrial facilities who were not specifically assigned to refractory work could nonetheless receive significant “bystander” exposures from working in the same areas as furnace liners or kiln workers. Asbestos fibers released during nearby refractory work readily dispersed throughout large industrial spaces and could settle on workers’ clothing, hair, and skin, posing a secondary risk of take-home exposure to family members as well.

Insulators, pipefitters, and other trades who worked at facilities using Quigley products may also have claims, particularly if they can document that they worked in proximity to refractory work or that Insulag was applied to surfaces they later disturbed or worked near. An experienced asbestos attorney can help evaluate the full scope of potential exposure sites and product contacts for any given worker’s occupational history.

Quigley Bankruptcy and the Pfizer-Backed Asbestos Trust

By the early 2000s, the volume of asbestos claims against Quigley had grown to a level that made continued operation as a going concern untenable. In September 2004, Quigley Co. filed for Chapter 11 bankruptcy protection in the United States Bankruptcy Court for the Southern District of New York. The filing was intended to allow Quigley to reorganize its asbestos liabilities through a court-supervised process and establish a Section 524(g) asbestos trust—the legal mechanism Congress created specifically to resolve mass asbestos tort liabilities in bankruptcy.

Section 524(g) of the Bankruptcy Code allows a reorganizing debtor to create a trust funded with assets contributed by the company (and potentially by related parties, including parent companies) that will serve as the exclusive remedy for all current and future asbestos claimants. In exchange for funding the trust, Pfizer and Quigley received a “channeling injunction” that directs all asbestos claims related to Quigley products to the trust and away from the courts—protecting both the reorganized entity and, critically, Pfizer itself from further direct litigation.

The Quigley bankruptcy was unusually contentious. Plaintiffs’ attorneys and certain creditor groups challenged Pfizer’s involvement in the plan and argued that the proposed trust funding was inadequate relative to the true value of pending claims. The litigation over plan confirmation dragged on for years, with multiple court rulings, appeals, and remands before a final plan was confirmed.

The confirmed Quigley Asbestos Trust operates under a Trust Distribution Procedure (TDP) that specifies what medical conditions are compensable, what evidence claimants must provide to establish disease and exposure, and what payment amounts are associated with each disease level. The current payment percentage—the fraction of a scheduled claim value that the trust actually pays—is approximately 14.5%. This means a claim with a scheduled value of $100,000 would receive a payment of approximately $14,500 from the trust.

The payment percentage may seem low, but it reflects the reality that asbestos trusts must remain solvent to pay claims from workers who are not yet diagnosed and may not develop mesothelioma for another 20 years. Trust administrators are required by law to project future claims and set the payment percentage at a level that ensures equitable treatment of all claimants, present and future. The Quigley Trust’s payment percentage is reviewed periodically and has been adjusted over time.

Importantly, a Quigley Trust claim is typically filed alongside claims against multiple other asbestos trusts and, potentially, direct litigation against solvent defendants. Workers with mesothelioma are often entitled to file claims against dozens of different trusts simultaneously, since they were commonly exposed to asbestos products from multiple manufacturers throughout their careers. The combined recoveries from multiple trust claims and litigation settlements can be substantially larger than any single trust payment might suggest.

Quigley Co. Product Lines and Key Facts

Frequently Asked Questions: Quigley Co. & Asbestos Claims